Lexeo (LXEO) - Company Profit

Corporate emblem and logo of Lexeo Therapeutics, Inc. (LXEO)

Lexeo Therapeutics (LXEO) specializes in developing innovative treatments for heart and brain pathologies. This price chart reflects profit dynamics, which currently stand at -0.09. High barriers to entry in the industry are ensured by exclusive patents for the transport of genetic material into tissues, as well as extremely complex certification regulations for biologics accessible only to leading scientists.

Company Net Income: lexeotx.com (LXEO) for 02/21/2024 - 10/30/2026

Comprehensive metric breakdowns and analytics for lexeotx.com (LXEO)

- stock value and consensus price forecast:
Market Price Lexeo Therapeutics, Inc.|LXEO - Consensus Target
- market capitalization indicators:
Market Capitalization Lexeo Therapeutics, Inc.|LXEO - Enterprise Value
- book capitalization information:
Net Asset Value per Share Lexeo Therapeutics|LXEO - Company Book Value|Market-to-Book Ratio lexeotx.com|LXEO - Cumulative Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Lexeo Therapeutics|LXEO - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Lexeo Therapeutics, Inc.|LXEO - Company Aggregate Debts|Debt to Net Assets Ratio Lexeo Therapeutics, Inc.|LXEO - Company Long-Term Debts|Short-Term Debt Lexeo Therapeutics|Intermediate Coverage Ratio lexeotx.com
- company profitability and valuation multiples indicators:
LXEO - Net Profit
Fundamental valuation:Lexeo (LXEO)
Manufactured products of Lexeo Therapeutics

The investment potential of Lexeo Therapeutics (LXEO) is based on the synergy between its scientific authority in Alzheimer's therapy and its financial stability. This metric captures the net remaining funds after deducting all operating and tax expenses from revenue. By analyzing the company's profit figures, an investor assesses the monetization efficiency of its unique gene developments. Positive momentum confirms the viability of the business model amidst costly research. This ensures capital preservation and confidence in long-term growth.

Direct competitors

Company Net Income Tempus AI (TEM)|Net Income QGEN|Company Profit IONS (ionispharma.com)|Net Profit RGEN|RNA - Company Net Income|Company Net Income CRISPR Therapeutics Corp CRSP|GeneDx Corp (WGS) - Company Net Income|RARE: Net Income|Final Profit BEAM (beamtx.com)|SRPT (Sarepta) - Net Income|TWST: Profit After Payment of Taxes|TXG (10x Genomics Corp) - Net Profit|NTLA: Final Profit|Net Profit STOK|BLFS - Company Net Income|Company Net Income Wave Life Sciences Ltd. WVE|Final Profit MAZE|Sionna Pharma - Net Profit|PRME - Net Profit|Taysha Gene Therapies (TSHA) - Company Net Income|Profit After Tax QURE (uniqure.com)|MGTX (MeiraGTx) - Net Profit|Company Net Income REGENXBIO Inc RGNX|Net Income SLDB (Solid Bio)|Net Profit Ocugen Pharma (OCGN)|Pacific Biosciences - Net Income|Profit After Payment of Taxes BNTC (benitec.com)|Design Therapeutics, Inc. - Net Profit|Net Financial Result Rocket Pharma RCKT|FDMT: Net Profit|Net Income Korro Bio|Company Net Income Editas Medicine, Inc.|silence-therapeutics.com (SLN) - Net Financial Result|Company Net Income ProQR Therapeutics N.V. (PRQR)|Company Net Income CDXS (codexis.com)|Sangamo - Net Income|NAUT: Company Profit|Metagenomi, Inc. - Net Profit|Company Net Income Precision BioSciences Inc.|generationbio.com (GBIO) - Company Net Income|Company Net Income Boundless Bio Inc. (BOLD)|XCUR (Exicure Inc.) - Net Profit|Company Profit IMNN (Celsion Corporation)|Company Net Income Phio Pharmaceuticals (PHIO)|mustangbio.com - Company Profit|Net Profit RNAZ (TransCode Therapeutics, Inc.)|Net Profit Bionano Genomics Inc. BNGO|APDN - Company Net Income|BLUE: Company Net Income|IPA: Net Profit|Company Net Income omegatherapeutics.com (OMGA)|Net Income OMIC|Company Profit RGLS (Regulus Therapeutics, Inc.)|Net Profit SYRS|TBIO - Company Net Income|Company Net Income TRACON Pharmaceuticals TCON|unitybiotechnology.com (UBX) - Company Net Income